- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01277692
A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.
27. juni 2017 oppdatert av: GlaxoSmithKline
A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Subjects
This study is a three Part, Phase 1, randomized, dose-escalation, fusion, placebo-controlled, double-blind study to determine the safety, tolerability and Pharmacokinetic (PK) profile of GSK2336805 in healthy subjects and the safety, tolerability, PK, and antiviral profile of GSK2336805 in subjects chronically infected with HCV: i. Single doses in healthy subjects and the effect of food on GSK2336805 PK (Part 1).
ii. Repeat doses in healthy subjects (Part 2) iii.
Single doses in chronically infected HCV positive subjects (Part 3).
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
58
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
California
-
Chula Vista, California, Forente stater, 91911
- GSK Investigational Site
-
-
Kansas
-
Lenexa, Kansas, Forente stater, 66219
- GSK Investigational Site
-
-
New Jersey
-
Willingboro, New Jersey, Forente stater, 08046
- GSK Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG, including no cardiac, pulmonary, hepatic, biliary (except Gilbert's disease, gastrointestinal, or renal (defined as serum creatinine >1.5 mg/dL or a calculated creatinine clearance (CrCl)<50 mL/min), disorders, or cancer within the past 5 years (except localized or in situ cancer of the skin). A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. A single repeat laboratory evaluation is allowed for eligibility determination.
- Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- A female is eligible to enter and participate in this study if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, bilateral oophorectomy, hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea.
- Male subjects must agree to use one of the contraception methods listed in the protocol.
- Body weight greater than or equal to 50 kg (110 lbs.) for men and greater than or equal to 45 kg (99 lbs.) for women. For Part 1, body mass index (BMI) between 18.5-32 kg/m2 inclusive will be allowed. For Part 3, BMI between 18.5-35.0 kg/m2 inclusive will be allowed.
- For healthy subjects in Part 1 and Part 2, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase, bilirubin, and creatinine less than the upper limits of normal (ULN) (isolated bilirubin <2.0xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- QTcB or QTcF < 450 msec; or QTc <480 msec in subjects with Bundle Branch Block.
- The subject's systolic blood pressure is inside the range of 90-140 mmHg, or diastolic blood pressure is inside the range of 45-90 mmHg or heart rate is inside the range of 50-100 beats per minute (bpm) for female subjects or 45-100 bpm for male subjects.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and is likely to complete the study as planned.
- The following are Supplemental inclusion criteria for Part 3: HCV positive subjects: Treatment naive chronically infected genotype 1 HCV patients, defined as infection for >6 months and no prior HCV therapy.
- An HCV RNA viral load of greater than 100,000 IU/mL using a COBAS TaqMan HCV test and HCV genotype 1a or 1b as assessed by VERSANT HCV genotyping LiPA 2.0 (Bayer Healthcare, Berkeley, California), or by direct Deoxyribonucleic acid (DNA) sequencing of the NS5B gene Hepatitis C virus infection of mixed genotype excluded. HCV subjects with mixed genotypes are not eligible for the study.
- ALT greater than or equal to 3x ULN is allowed.
- Liver biopsy within two years prior to screening indicating the absence of cirrhosis.
Exclusion Criteria:
- Unwillingness or inability to follow the procedures outlined in the protocol.
- A positive pre-study test for Human Immunodeficiency Virus (HIV) antibody or Hepatitis B surface antigen.
- For healthy subjects in Parts 1 and 2, a positive Hepatitis C antibody result within 3 months of screening. Chronic HCV infected subjects in Part 3 will have a positive HCV antibody and a positive HCV RNA.
- Pregnant females as determined by positive serum or urine Human chorionic gonadotropin (hCG) test at screening or prior to dosing.
- Subject is mentally or legally incapacitated.
- Has a history of regular alcohol consumption averaging: >7 drinks/week for women or >14 drinks/week for men within 6 months of the screening visit.
- Unwilling to abstain from alcohol for 48 hours prior to the start of dosing until collection of the final pharmacokinetic sample during each treatment period.
- For healthy subjects in Parts 1 and 2, history of regular use of tobacco- or nicotine-containing products within 3 months of the screening visit or indication of tobacco use as evidenced by a positive urine cotinine test at screening. For chronic HCV infected subjects in Part 3, history of regular use of tobacco- or nicotine-containing products is allowed; however, use of tobacco is not allowed on days of PK draws nor at the study site.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos, satsuma, ugli, tangerine, and tangelo, exotic citrus fruits, grapefruit hybrids or fruit juices from 5 days prior to the first dose of study medication.
- The subject has a positive pre-study drug screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, phencyclidine (PCP), and benzodiazepines. Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new investigational entities within 12 months prior to the first dosing day.
- History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Holter monitoring shows one or more of the following: Any symptomatic arrhythmia (except isolated extra systoles); Sustained cardiac arrhythmias (such as atrial fibrillation or flutter, sustained ventricular tachycardia (SVT) (>10 consecutive beats)); Non-sustained or sustained ventricular tachycardia (defined as >3 consecutive ventricular ectopic beats); Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular (AV) block [2nd degree or higher in an awake subject], Wolff-Parkinson-White syndrome (WPW) syndrome, other pre-excitation syndromes); Symptomatic sinus pause or sinus pause >3 seconds - unless patient is straining, vomiting, or having some other type of hypervagal response; 300 or more supraventricular ectopic beats in 24 hours; 250 or more ventricular ectopic beats in 24 hours; Ischemia, diagnosed by a sequence of EKG changes that include flat or down sloping ST-segment depression >0.1 mV, with a gradual onset and offset that lasts for a minimum period of 1 minute. Each episode of ischemia must be separated by a minimum duration of at least 1 minute, during which the ST segment returns back to baseline (1x1x1 rule)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Part 1: Single Dose Escalation in Healthy Subjects
The doses currently planned are 10, 30mg, 100mg, 200mg
|
single dose once daily
single dose once daily
single dose once daily
single dose once daily
single dose in HCV infected patients
|
Eksperimentell: Part 2: Repeat Dose Escalation in Healthy Subjects
The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
|
repeat dose once daily for 7 days
repeat dose once daily for 7 days
|
Eksperimentell: Part 3: Single Dose Escalation in HCV Infected Subjects
The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
|
single dose once daily
single dose in HCV infected patients
single dose in HCV infected patients
single dose in HCV infected patients
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
GSK2336805 safety parameters : adverse events
Tidsramme: Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
GSK2336805 safety parameters: telemetry
Tidsramme: Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
GSK2336805 safety parameters: absolute values and changes over time of hematology, clinical chemistry, urinalysis
Tidsramme: Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
GSK2336805 safety parameters: vital signs (blood pressure, heart rate)
Tidsramme: Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
GSK2336805 safety parameters: electrocardiogram (ECG) parameters
Tidsramme: Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
Part 1 change from baseline for 14 days; Part 2 change from baseline for 24 days; Part 3 change from baseline for 16 days
|
GSK2336805 PK parameters following single dose administration: area under the plasma concentration curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following single dose administration: area under the plasma concentration curve over the dosing interval AUC(0-tau))
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following single dose administration: maximum observed concentration (Cmax)
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following single dose administration: time to maximum observed concentration (tmax)
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following single dose administration: observed concentration at 24h post-dose (C24)
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following single dose administration: terminal half-life (t1/2)
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following single dose administration: lag time (tlag)
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following single dose administration: apparent clearance (CL/F)
Tidsramme: Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
Part 1 up to 48 hours; Part 2 for 7 and 14 days; Part 3 for 48 hours
|
GSK2336805 PK parameters following repeat dose administration:AUC(0-tau)
Tidsramme: Day 7 and Day 14
|
Day 7 and Day 14
|
GSK2336805 PK parameters following repeat dose administration: Pre-dose (trough) concentration at the end of the dosing interval Ctau
Tidsramme: Day 7 and Day 14
|
Day 7 and Day 14
|
GSK2336805 PK parameters following repeat dose administration: Cmax
Tidsramme: Day 7 and Day 14
|
Day 7 and Day 14
|
GSK2336805 PK parameters following repeat dose administration: tmax
Tidsramme: Day 7 and Day 14
|
Day 7 and Day 14
|
GSK2336805 PK parameters following repeat dose administration: t1/2,
Tidsramme: Day 7 and day 14
|
Day 7 and day 14
|
GSK2336805 PK parameters following repeat dose administration: CL/F
Tidsramme: Day 7 and Day 14
|
Day 7 and Day 14
|
GSK2336805 PK parameters following single dose in HCV infected subjects: AUC(0-infinity) or AUC(0 - tau)
Tidsramme: for 48 hours
|
for 48 hours
|
GSK2336805 PK parameters following single dose in HCV infected subjects: Cmax
Tidsramme: for 48 hours
|
for 48 hours
|
GSK2336805 PK parameters following single dose in HCV infected subjects: C24
Tidsramme: for 48 hours
|
for 48 hours
|
GSK2336805 PK parameters following single dose in HCV infected subjects: tmax
Tidsramme: for 48 hours
|
for 48 hours
|
GSK2336805 PK parameters following single dose in HCV infected subjects: tlag
Tidsramme: for 48 hours
|
for 48 hours
|
GSK2336805 PK parameters following single dose in HCV infected subjects: CL/F
Tidsramme: for 48 hours
|
for 48 hours
|
HCV Ribonucleic acid (RNA) viral load reduction from baseline during the 24hr and post-dosing following a single dose of GSK2336805 in HCV subjects
Tidsramme: at baseline, 24 hours, and for 16 days
|
at baseline, 24 hours, and for 16 days
|
HCV RNA change from baseline to nadir (maximum change) in HCV subjects
Tidsramme: baseline, and for 16 days
|
baseline, and for 16 days
|
Time course of HCV viral load at baseline, after dosing with GSK2336805, and for greater than or equal to 2 weeks after GSK2336805 dosing (Part 3)
Tidsramme: baseline and up to 16 days
|
baseline and up to 16 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
GSK2336805 PK parameters: AUC(0-infinity) or AUC (0 - tau) following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)
Tidsramme: 48 hours
|
48 hours
|
GSK2336805 PK parameters: Cmax following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)
Tidsramme: 48 hours
|
48 hours
|
GSK2336805 PK parameters: tmax following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)
Tidsramme: 48 hours
|
48 hours
|
GSK2336805 PK parameters: tlag following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)
Tidsramme: 48 hours
|
48 hours
|
GSK2336805 AUC(0-tau) on Day 7 compared to AUC(0-24) on Day 1 to estimate accumulation ratio (R) and GSK2336805 AUC(0-tau) on Day 7 compared to AUC(0-infinity) on Day 1
Tidsramme: Day 1 and Day 7
|
Day 1 and Day 7
|
Pre-dose concentrations (Ctau) on Day 2 through 7 to assess the achievement of steady state of GSK2336805 following repeat administration (Part 2)
Tidsramme: Day 2 through Day 7
|
Day 2 through Day 7
|
GSK2336805 PK parameters: AUC(0-infinity), AUC(0-t), Cmax, and C24 following single dose administration
Tidsramme: 48 hours
|
48 hours
|
GSK2336805 PK parameters: AUC(0-τ), Cτ, and Cmax following repeat administration
Tidsramme: for 7 days
|
for 7 days
|
Correlation between concentration and various safety parameters, if appropriate
Tidsramme: 16 days
|
16 days
|
Sequence analysis of the viral quasispecies as appropriate (Part 3).
Tidsramme: 16 days
|
16 days
|
GSK2336805 AUC(0-tau) on Day 14 compared to AUC(0-24) on Day 1 to estimate accumulation ratio (R) and GSK2336805 AUC(0-tau) on Day 14 compared to AUC(0-inf) on Day 1
Tidsramme: 14 days
|
14 days
|
Pre-dose concentrations (Ctau) on Day 2 through 14 to assess the achievement of steady state of GSK2336805 following repeat administration (Part 2 Cohort E)
Tidsramme: Day 2 and Day 14
|
Day 2 and Day 14
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
3. november 2010
Primær fullføring (Faktiske)
9. mai 2011
Studiet fullført (Faktiske)
9. mai 2011
Datoer for studieregistrering
Først innsendt
13. januar 2011
Først innsendt som oppfylte QC-kriteriene
13. januar 2011
Først lagt ut (Anslag)
17. januar 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
28. juni 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
27. juni 2017
Sist bekreftet
1. juni 2017
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 114885
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hepatitt C
-
Dokuz Eylul UniversityEge UniversityFullførtMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CTyrkia
-
Tripep ABInovio PharmaceuticalsUkjentKronisk hepatitt C virusinfeksjonSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTilbaketrukketKronisk hepatitt C virusinfeksjonIsrael
-
Hadassah Medical OrganizationUkjentKronisk hepatitt C virusinfeksjonIsrael
-
Johann Wolfgang Goethe University HospitalFullført
-
Beni-Suef UniversityFullførtٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin og HCV genotype 4-infiserte egyptisk erfarne deltakereKronisk hepatitt C virusinfeksjonEgypt
-
University College CorkDupont Applied BiosciencesRekruttering
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C genotype 1 | Hepatitt C (HCV) | Hepatitt C viral infeksjonForente stater, New Zealand
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C (HCV) | Hepatitt C genotype 4 | Hepatitt C viral infeksjonForente stater
-
Meir Medical CenterFullførtUtvikle ny teknikk for å måle C/D-forhold fra digitale stereooptiske plater | Intraobserver reproduserbarhet av C/D-målinger | Interobservatørvariabilitet av C/D-målinger
Kliniske studier på GSK2336805 10mg
-
Hanmi Pharmaceutical Company LimitedFullførtPrimær hyperkolesterolemiKorea, Republikken
-
Yokohama City UniversityRekruttering
-
International University of Health and WelfareAvsluttet
-
Chong Kun Dang PharmaceuticalUkjentType II diabetes mellitusKorea, Republikken
-
GlaxoSmithKlinePPDFullførtHepatitt C, kroniskPuerto Rico, Forente stater
-
IlDong Pharmaceutical Co LtdFullført
-
GlaxoSmithKlinePPDFullførtHepatitt C, kroniskPuerto Rico, Forente stater, Bulgaria, Tyskland, Belgia, Frankrike
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityFullført
-
GlaxoSmithKlineFullførtHepatitt CForente stater
-
Stealth BioTherapeutics Inc.Fullført